Bayer wins FDA breakthrough therapy designation for NSCLC candidate
Pharmaceutical Technology
FEBRUARY 26, 2024
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
Mon.Feb 26, 2024
331 
Obesity drug from Boehringer, Zealand succeeds in MASH trial
Bio Pharma Dive
FEBRUARY 26, 2024
Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Merck’s Keytruda regimen gains positive EMA CHMP opinion
Pharmaceutical Technology
FEBRUARY 26, 2024
Merck's KEYTRUDA has received a positive opinion from the EMA CHMP for use in combination with chemotherapy for non-small cell lung cancer.
Simple Experiment Reveals Why Your Next Antibiotics May Prove Useless
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 26, 2024
Do bacteria mutate randomly, or do they mutate for a purpose? Researchers have been puzzling over this conundrum for over a century. In 1943, microbiologist Salvador Luria and physicist turned biologist Max Delbrück invented an experiment to argue that bacteria mutated aimlessly.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
SK bioscience’s typhoid vaccine receives WHO prequalification
Pharmaceutical Technology
FEBRUARY 26, 2024
SK bioscience has achieved a significant milestone with its typhoid conjugate vaccine, SKYTyphoid, receiving WHO prequalification.
Panel asks govt to persuade private insurance companies to cover Ayush treatments
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 26, 2024
The Department-related Parliamentary Standing Committee on Health and Family Welfare has recommended to the government to persuade private insurance companies to include Ayurveda, Yoga, Unani, Siddha and Homoeopathy (Ayush) treatments in their products and look at global acceptance for these systems of medicines through legalisation and insurance support in other countries.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Biogen receives EMA CHMP recommendation for ALS drug Qalsody
Pharmaceutical Technology
FEBRUARY 26, 2024
The EMA's decision on the marketing authorisation application for Biogen Qalsody is expected in Q2 of this year.
Choosing laboratory equipment with workplace experience in mind
Bio Pharma Dive
FEBRUARY 26, 2024
Making equipment choices with employee experience in mind can help researchers build top-performing teams while enhancing operational efficiencies.
FDA clears PK Med to streamline gout injectable to Phase II
Pharmaceutical Technology
FEBRUARY 26, 2024
The Phase II prospective, randomised trial will evaluate three doses of PKM-01 to select the optimal dosage for a Phase III study.
February 26, 2024: In PRIM-ER Qualitative Study, EM Talk Program Improved Serious Illness Conversation Skills
Rethinking Clinical Trials
FEBRUARY 26, 2024
Dr. Oluwaseun Adeyemi, lead author of the report Communication skills training using the EM Talk model reached a high proportion of clinicians in participating emergency departments and improved their serious illness conversation skills, according to a qualitative study conducted as part of the PRIM-ER trial. The observed reach and effectiveness of the training program has the potential to improve use of these skills in clinical practice.
Streamlining supply chain operations in focus at Clinical Trial Supply Europe 2024
Pharmaceutical Technology
FEBRUARY 26, 2024
The upcoming Clinical Trial Supply Europe 2024 conference will round-up pharma and biotech delegates to discuss the trends and challenges in clinical trial supply industry.
PhaSER Biomedical receives $2.3m drug discovery grant from the Gates Foundation
Pharma Times
FEBRUARY 26, 2024
Every year, tuberculosis, malaria and HIV cause over five million deaths worldwide
FDA approves Alvotech-Teva’s SIMLANDI jab for multiple conditions
Pharmaceutical Technology
FEBRUARY 26, 2024
The US FDA has granted approval for Alvotech and Teva Pharmaceuticals’ SIMLANDI injection, which is an interchangeable biosimilar to Humira.
Researchers develop terahertz biosensor to detect skin cancer for early diagnosis
Pharma Times
FEBRUARY 26, 2024
Results from the study could also be used for other forms of cancer and diseases
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Moderna concludes construction at new mRNA vaccine facility in Canada
Pharmaceutical Technology
FEBRUARY 26, 2024
Moderna has announced the conclusion of construction works at its new mRNA manufacturing facility in Canada.
NGM to go private through deal with investment firm
Bio Pharma Dive
FEBRUARY 26, 2024
The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.
Bristol Myers blueprints $400M Ireland expansion with plans to add sterile drug firepower and hire 350
Fierce Pharma
FEBRUARY 26, 2024
Bristol Myers Squibb’s first drug substance facility outside the United States is now set to become the company’s inaugural sterile drug product (SDP) facility in Europe, thanks to a multi-million- | Bristol Myers Squibb’s first drug substance facility outside the United States is now set to become the company’s inaugural sterile drug product (SDP) facility in Europe, thanks to a multi-million-dollar expansion expected to add hundreds of new jobs in the coming years.
GSK drug meets goal in late-stage gonorrhea study
Bio Pharma Dive
FEBRUARY 26, 2024
The drug, one of several GSK is developing for drug-resistant bacteria, has now succeeded in testing against two different infections.
Sanofi trumpets win for oral BTK drug in chronic hives
pharmaphorum
FEBRUARY 26, 2024
Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.
Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma
Drug Patent Watch
FEBRUARY 26, 2024
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic… The post Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma appeared first on DrugPatentWatch - Make Better Decisions.
GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial
pharmaphorum
FEBRUARY 26, 2024
GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.
Neuraxpharm launches new multiple sclerosis treatment in Europe
BioPharma Reporter
FEBRUARY 26, 2024
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the first launch of BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Shionogi takes Akili’s ADHD digital therapy to Japan
pharmaphorum
FEBRUARY 26, 2024
Digital health company Akili expands beyond the US as partner Shionogi files for approval for its ADHD digital therapeutic (DTx) in Japan
Vir Biotechnology sees highest patent filings and grants during November in Q4 2023
Pharmaceutical Technology
FEBRUARY 26, 2024
Access and buy GlobalData’s databook on the latest filings and grants activity for Vir Biotechnology here.
Amgen boots up Ohio 'smart facility' where it plans to employ 400—and a trio of robots, too
Fierce Pharma
FEBRUARY 26, 2024
Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” | Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” Dubbed “Amgen Ohio,” the nearly 300,000-square-foot biomanufacturing plant in New Albany, Ohio, is set to employ 400 full-time employees and leverage the “latest innovation and technology.
Praxis Precision Medicines sees highest patent filings and grants during November in Q4 2023
Pharmaceutical Technology
FEBRUARY 26, 2024
Access and buy GlobalData’s databook on the latest filings and grants activity for Praxis Precision Medicines here.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
With global expansion planned, Krystal lays out blockbuster ambitions for topical gene therapy
Fierce Pharma
FEBRUARY 26, 2024
Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million. Now, the company is looking toward bringing the drug to Europe and Japan and testing a new eye-drop formulation.
Arcutis Biotherapeutics sees highest patent filings and grants during October in Q4 2023
Pharmaceutical Technology
FEBRUARY 26, 2024
Access and buy GlobalData’s databook on the latest filings and grants activity for Arcutis Biotherapeutics here.
Boehringer’s survodutide shows monster MASH potential
pharmaphorum
FEBRUARY 26, 2024
Boehringer Ingelheim and Zealand Pharma report stellar top-line results for GLP-1/glucagon agonist survodutide in liver disease MASH.
Krystal Biotech sees highest patent filings and grants during October in Q4 2023
Pharmaceutical Technology
FEBRUARY 26, 2024
Access and buy GlobalData’s databook on the latest filings and grants activity for Krystal Biotech here.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content